Table 3 Changes from baseline in CMV and EBV viral load in patients receiving placebo or tofacitinib 2 mg, 5 mg or 15 mg BID
Baseline status | Post-baseline status | Chi-squared p value (vs placebo) | Overall p value (vs baseline) | ||
|---|---|---|---|---|---|
Patients with CMV undetectable at baseline | Undetectable N (n) | Remained undetectable n (%) | Became detectable n (%) | ||
Placebo | 49 (46) | 44 (95.7) | 2 (4.3) | N/A | 0.0001 |
Tofacitinib 2 mg BID | 48 (46) | 41 (89.1) | 5 (10.9) | 0.2381 | |
Tofacitinib 5 mg BID | 48 (45) | 42 (93.3) | 3 (6.7) | 0.6274 | |
Tofacitinib 15 mg BID | 49 (48) | 32 (66.7) | 16 (33.3) | 0.0004 | |
Patients with CMV detectable at baseline a | Detectable N (n) | Remained detectable n (%) | Became undetectable n (%) | ||
Placebo | 1 (1) | 0 (0) | 1 (100.0) | N/A | – |
Tofacitinib 2 mg BID | 1 (1) | 0 (0) | 1 (100.0) | – | |
Tofacitinib 5 mg BID | 1 (1) | 0 (0) | 1 (100.0) | – | |
Tofacitinib 15 mg BID | 0 (0) | 0 (0) | 0 (0) | – | |
Patients with EBV undetectable at baseline | Undetectable N (n) | Remained undetectable n (%) | Became detectable n (%) | ||
Placebo | 28 (20) | 18 (90.0) | 2 (10.0) | N/A | 0.0122 |
Tofacitinib 2 mg BID | 30 (25) | 14 (56.0) | 11 (44.0) | 0.0124 | |
Tofacitinib 5 mg BID | 26 (19) | 15 (78.9) | 4 (21.1) | 0.3390 | |
Tofacitinib 15 mg BID | 31 (28) | 14 (50.0) | 14 (50.0) | 0.0038 | |
Patients with EBV detectable at baseline | Detectable N (n) | Remained detectable n (%) | Became undetectable n (%) | ||
Placebo | 21 (19) | 9 (47.4) | 10 (52.6) | N/A | 0.1299 |
Tofacitinib 2 mg BID | 18 (13) | 9 (69.2) | 4 (30.8) | 0.2208 | |
Tofacitinib 5 mg BID | 21 (14) | 10 (71.4) | 4 (28.6) | 0.1669 | |
Tofacitinib 15 mg BID | 17 (14) | 12 (85.7) | 2 (14.3) | 0.0236 | |